Caplin Point Laboratories Ltd.
Snapshot View

781.25 -19.25 ▼-2.4%

20 May 2022, 12:35:59 PM
Volume: 185,202

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.caplinpoint.net
Market Cap 6,028.42 Cr.
Enterprise Value(EV) 5,462.46 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 39.56 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 20.11 Trailing Twelve Months Ending 2022-03
Industry PE 28.47 Trailing Twelve Months Ending 2022-03
Book Value / Share 195.77 Trailing Twelve Months Ending 2022-03
Price to Book Value 4.07 Calculated using Price: 796.35
Dividend Yield 0.25 Period Ending 2021-03
No. of Shares Subscribed 7.58 Cr. 75,800,542 Shares
FaceValue 2
Company Profile

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.40%
1 Week
+10.42%
1 Month
-0.90%
3 Month
+1.71%
6 Month
-7.32%
1 Year
+33.74%
2 Year
+144.26%
5 Year
+31.61%
10 Year
9 years 2013-06 2014-06 2015-06 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 40.49 53.24 55.78 43.13 54.97 49.43 37.14 29.58 25.65
Return on Capital Employed (%) 56.69 68.99 71.11 55.41 69.03 64.08 45.59 33.35 28.82
Return on Assets (%) 11.59 16.48 20.12 18.46 30.54 33.68 28.41 23.02 20.20

Balance Sheet View Details

Particulars 10 years 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 43 62 93 128 225 364 633 948 1,186 1,484
Non Curr. Liab. 9 10 10 14 20 28 23 25 17 13
Curr. Liab. 83 108 125 125 113 109 86 144 143 208
Minority Int. 0 0 0 0 0 0 0 9 18 26
Equity & Liab. 135 180 229 267 358 500 743 1,126 1,364 1,730
Non Curr. Assets 96 131 147 149 179 196 249 303 328 432
Curr. Assets 39 49 82 119 179 304 494 823 1,036 1,298
Misc. Exp. not W/O
Total Assets 135 180 229 267 358 500 743 1,126 1,364 1,730

Profit Loss View Details

Particulars 10 years 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 127 173 252 239 402 540 649 863 1,061 1,269
Other Income 2 4 3 4 10 13 19 41 24 39
Total Income 129 177 255 242 412 553 668 905 1,085 1,308
Total Expenditure -105 -137 -192 -175 -277 -345 -417 -603 -733 -875
PBIDT 24 40 63 68 135 208 251 301 352 433
Interest -1 -1 -1 0 -1 -1 -1 0 -2 -1
Depreciation -2 -4 -8 -7 -13 -19 -23 -32 -37 -47
Taxation -8 -10 -12 -14 -25 -44 -50 -54 -62 -77
Exceptional Items
PAT 14 26 41 46 96 145 177 215 251 308
Minority Interest 0 0 0 0 0 0 -9 -9
Share Associate
Other Related Items
Consolidated Net Profit 14 26 41 46 96 145 177 215 242 300
Adjusted EPS 2 3 5 6 13 19 23 28 32 40

Cash Flow View Details

Particulars 10 years 2012-06 Rs. Cr. 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 28 32 60 50 42 68 66 83 45 266
Cash Fr. Inv. -16 -45 -44 -23 -6 -36 -69 -100 -55 -5
Cash Fr. Finan. -1 -1 -6 -9 -14 -7 -12 90 80 -24
Net Change 10 -15 10 19 23 25 -14 73 70 236
Cash & Cash Eqvt 32 17 27 45 68 91 77 151 221 457

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 69.03 69.03 69.03 69.03 69.03 69.03 69.03 68.91 68.89
Public 30.97 30.97 30.97 30.97 30.97 30.97 30.97 31.09 31.11
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 19 May 2022
Spurt in Volume
CAPLIPOINT : Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.
Thu, 19 May 2022
Spurt in Volume
CAPLIPOINT : Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.
Wed, 18 May 2022
Record Date
Caplin Point Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 24-May-2022.

Technical Scans View Details

Thu, 19 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Above Previous High Closing Above Previous High
Making Higher Highs for 3 days Making Higher Highs for 3 days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 212,197.18 909.50 +2.8%
Divi's Laboratories Ltd. 111,510.08 4,292.00 +2.2%
Cipla Ltd. 75,683.19 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. 65,571.78 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. 52,245.59 3,648.75 +0.5%
Gland Pharma Ltd. 51,277.11 3,050.00 -1.6%
Piramal Enterprises Ltd. 45,274.50 1,914.15 +1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 32.93 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-12 43.43 4,292.00 +2.2%
Cipla Ltd. Consolidated 2022-03 30.07 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 30.04 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.10 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-12 43.23 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-12 36.44 1,914.15 +1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.11 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.30 4,292.00 +2.2%
Cipla Ltd. Consolidated 2022-03 3.63 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.41 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.44 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-12 7.47 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.28 1,914.15 +1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,292.00 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,914.15 +1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,292.00 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,914.15 +1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,292.00 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,914.15 +1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,292.00 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,914.15 +1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 909.50 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,292.00 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 969.85 +3.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,201.70 +6.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,648.75 +0.5%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,050.00 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,914.15 +1.1%